Dewayne A Fox

Plain English
This study examined a type of cancer related to primary sclerosing cholangitis (PSC), which is known to be deadly for those who have it. Researchers looked at the medical records of 62 patients with PSC-related biliary tract cancer (BTC) and compared their outcomes to 146 patients with non-PSC-related BTC. They found that adding immunotherapy to chemotherapy helped patients with PSC-related BTC stay cancer-free longer (about 12.2 months compared to 4.7 months) and that such treatments were generally safe. Who this helps: This information benefits patients with PSC-related cancer and the doctors treating them.

Plain English
This study looked at the salivary glands of patients with Sjögren's Disease to understand how cell interactions and metabolism are connected to the disease. Researchers found that certain cells in the glands showed increased activity related to lipid metabolism, which linked to higher immune activity and worsening of symptoms; specifically, levels of specific metabolic regulators were higher in the diseased tissue. Understanding these processes helps identify potential new treatments for Sjögren's Disease. Who this helps: Patients with Sjögren's Disease.

Plain English
This study looked at how a protein called TWEAK and its receptor Fn14 influence inflammation in rheumatoid arthritis (RA) and how this might affect the effectiveness of TNF inhibitors, a common treatment for the disease. Researchers found that higher levels of Fn14 were associated with more inflammation in RA cells and that blocking Fn14 reduced inflammation-causing substances by about 30-50%. This is important because it suggests targeting TWEAK/Fn14 could improve treatment responses for patients who don't benefit from standard TNF inhibitor therapies. Who this helps: This helps patients with rheumatoid arthritis who may not respond well to current treatments.

Plain English
This study looked at individuals with high levels of anti-CCP antibodies to understand what immune changes occur in those who go on to develop rheumatoid arthritis (RA) compared to those who don’t. The researchers found that people who developed RA had larger amounts of certain immune cell types and specific immune markers, which could signal the onset of the disease. Notably, they were able to create a model using these immune markers and other clinical signs to predict who would develop RA, offering a way to identify at-risk patients earlier. Who this helps: This helps patients at risk for rheumatoid arthritis and their doctors to identify disease onset sooner.

Plain English
In this study, researchers looked at a substance called soluble CD13 (sCD13) in patients with systemic sclerosis, a disease that can cause skin and organ fibrosis. They found that while sCD13 levels were higher in these patients compared to healthy individuals, they did not correlate with the severity of vascular issues or skin disease at baseline. However, in the early stages of the disease, higher levels of sCD13 indicated that patients were likely to see more improvement in skin fibrosis over the following year. Who this helps: This research can benefit patients with systemic sclerosis by providing insights into monitoring disease progression and treatment responses.

Plain English
This study focused on a condition called systemic sclerosis (SSc), an autoimmune disease that leads to thickening and scarring of the skin. Researchers found that certain proteins (CD13 and B1 receptor) were more active in the skin of patients with a severe form of SSc, contributing to excessive scar formation. By blocking the B1 receptor, they were able to reduce the fibrosis-related responses in lab tests and in mice, showing that this approach could be a new way to treat SSc. Who this helps: This helps patients with systemic sclerosis and their doctors by potentially offering a new treatment option.

Plain English
This study focused on a patient with a specific type of advanced colorectal cancer that has a BRAF mutation. The treatment approach used a combination of three drugs: vemurafenib, cetuximab, and chemotherapy, which led to a complete recovery for the patient despite initially having a severe condition. This is important because it shows that combining targeted therapies can produce strong positive outcomes, even in challenging cases. Who this helps: This helps patients with BRAF-mutated metastatic colorectal cancer.

Plain English
This study looked at the experiences of young people who identify as gender-diverse and also suffer from chronic pain. Researchers spoke with 19 youth and found that many felt their pain and gender identity were not taken seriously, and they often faced additional stress from their gender identity while also finding joy that helped them cope with pain. This is important because it highlights the need for healthcare to be more understanding and inclusive of the specific challenges faced by gender-diverse youth in managing chronic pain. Who this helps: This helps gender-diverse youth dealing with chronic pain and the healthcare providers who treat them.

Plain English
This study examined the role of a protein called CD6, which is found on certain immune cells. Researchers found that CD6 is linked to more than 15 diseases, particularly autoimmune conditions, and it may play a role in cancer treatment as a therapy target. Understanding CD6's functions could lead to better ways to treat these diseases, helping more patients manage their health effectively. Who this helps: Patients with autoimmune diseases and cancer.

Plain English
This study focused on a patient with advanced lung cancer who was treated with a medication that combines an antibody with a cancer drug, which caused a lung inflammation called pneumonitis. The patient managed to continue their treatment thanks to a new steroid regimen that allowed for the control of lung issues without needing to stop the effective cancer therapy. This approach could help doctors better manage similar lung problems in patients taking these types of cancer drugs, leading to improved care and outcomes. Who this helps: Patients with non-small cell lung cancer receiving antibody-drug conjugates.

Plain English
This study looked at a substance called soluble CD13 (sCD13), which is produced during COVID-19 infections. Researchers found that patients with severe COVID-19 had much higher levels of sCD13, and this was linked to increased inflammation and complications. Specifically, elevated sCD13 levels were associated with heightened immune response processes that lead to blood vessel stress and clot formation. Who this helps: This research benefits COVID-19 patients and doctors by highlighting possible targets for new treatments.

Plain English
This study looked at different types of antinuclear antibodies (ANAs) in patients with systemic lupus erythematosus (SLE) and how they respond to treatments that target B cells. The researchers found that anti-Smith and anti-RNP antibodies changed levels more often than others, like anti-SS-A/SS-B. Specifically, the levels of anti-Smith and anti-dsDNA dropped significantly after treatment, but only the drop in anti-dsDNA was linked to improvement in patients' health. Who this helps: This helps patients with systemic lupus erythematosus and their doctors in understanding the effectiveness of treatments.

Plain English
This study focused on Kaposiform lymphangiomatosis (KLA), a condition where lymphatic vessels grow too much and don't function properly. Researchers found that lymphatic cells with a specific change in the NRAS gene had different characteristics: they changed shape, moved and multiplied more, and produced higher levels of certain signaling molecules. This is important because it helps us understand how KLA develops and could lead to new treatment options. Who this helps: Patients with Kaposiform lymphangiomatosis and their doctors.

Plain English
This study tested whether hydroxychloroquine (HCQ) could prevent rheumatoid arthritis (RA) in people who are at high risk due to specific antibody levels. Out of 144 participants, 30.4% who took HCQ developed RA after 3 years, compared to 32.9% in the placebo group, showing HCQ did not significantly lower the risk of developing RA. These findings matter because they indicate that HCQ is not effective for preventing RA in these at-risk individuals, which could change treatment approaches. Who this helps: This helps patients at risk for rheumatoid arthritis and their doctors.

Plain English
This study looked at how different laboratories measure specific antibodies related to antiphospholipid syndrome, which is important for diagnosing this condition accurately. Out of 489 labs, the most common testing method used was an enzyme-linked immunosorbent assay (ELISA), chosen by 58.6% of responders, while 92.9% used the reference ranges provided by manufacturers for their results. These findings highlight the need for standardized testing and reporting to reduce misdiagnosis and improve patient care. Who this helps: This helps patients with antiphospholipid syndrome and healthcare providers involved in their care.

Plain English
The study examined how the T cell marker CD6 interacts with its receptors, particularly focusing on a newly identified receptor called CD44. The researchers found that when CD6 binds to CD44 and two other known receptors, it leads to significant changes in the structure of retinal pigment epithelial (RPE) cells, which are crucial for maintaining eye health. Specifically, this binding prompts changes in cell components that weaken the barrier these cells create, which can contribute to inflammation and tissue damage. Who this helps: This research benefits patients with inflammatory conditions affecting the eyes, as well as healthcare professionals working in this area.

Plain English
This research looks at new potential treatments for rheumatoid arthritis, focusing on specific molecules in the body that could be targeted to improve symptoms. The study highlights several promising targets, including CD40, PD-1, and GM-CSF, among others, which are currently being tested as new drugs. Finding effective treatments is crucial because rheumatoid arthritis can significantly impact a person's quality of life, making it essential to explore all possible options. Who this helps: This helps patients with rheumatoid arthritis who are seeking better treatment options.

Plain English
This study examined how siponimod, a medication approved for treating a form of multiple sclerosis called secondary progressive MS (SPMS), protects brain cells from damage caused by inflammation. Researchers found that siponimod significantly reduced cell death triggered by the inflammatory substance TNF-alpha in both rat and human brain cells, suggesting it helps to keep brain cells alive during neuroinflammation. This matters because it could lead to better treatment options for progressive forms of MS, which currently have limited effective therapies. Who this helps: This helps patients with secondary progressive multiple sclerosis.

Plain English
This paper studied the role of a protein called CD6 in T cells and how it interacts with other proteins in cancer. Researchers found that CD6 binds to three different proteins (CD166, CD318, and CD44) that are often present in cancer cells and are linked to worse outcomes for patients. Understanding these interactions could help improve cancer treatments and lead to better outcomes for patients. Who this helps: This benefits cancer patients and doctors working in oncology.

Plain English
This study investigated how a special antibody, UMCD6, affects immune cells that fight cancer. Researchers found that UMCD6 helps these immune cells, particularly natural killer (NK) cells and certain T cells, become more effective at killing cancer cells in mice with breast and prostate cancer, leading to improved survival rates. Specifically, treated mice had more powerful immune cells that were better positioned to attack tumors compared to those treated with a standard antibody. Who this helps: This benefits cancer patients by potentially improving treatments that enhance their immune responses to tumors.

Plain English
This study looked at two cases of teenagers who developed dangerously high levels of vitamin D, which can lead to serious health issues like kidney problems. In both cases, the boys had been using a creatine supplement that unexpectedly contained extremely high amounts of vitamin D—425,000 IU per serving, well above safe limits. It's important to recognize that dietary supplements can contain harmful ingredients, even if they don’t list them on the label. Who this helps: This research benefits patients using dietary supplements, doctors who take their medical history, and health regulators overseeing supplement safety.

Plain English
This study looked at a new lab test designed to check if chemicals are harmful to brain development in humans. The expert panel found that while this new test can be useful for initial screening, it isn't enough on its own to determine if a chemical is dangerous for human brain development. They emphasized that more research is needed to improve the test before it can be used in official safety regulations. Who this helps: This helps regulators, ensuring that chemicals are tested more effectively for safety regarding human brain development.

Plain English
This study looked at two patients with a disease related to myelin, a protective covering in the nervous system, who had COVID-19. One patient developed vision problems just two days after getting COVID-19, while the other experienced similar issues six months later. Both patients showed increased immune responses specifically linked to their condition and COVID-19, indicating a connection between the virus and their disease. Who this helps: This information benefits patients with myelin-related diseases and their doctors.

Plain English
This study investigated how a specific type of antibody that targets a receptor called SIRPα can help reduce inflammation in chronic conditions like rheumatoid arthritis and inflammatory bowel disease. Researchers found that in patients with these diseases, levels of the SIRPα protein were increased, particularly in those not responding to traditional treatments. When tested in models of arthritis and colitis, the new antibody significantly lowered inflammation by decreasing the presence of harmful immune cells in the affected tissues. Who this helps: This helps patients with chronic inflammatory diseases, particularly those who do not respond to current treatments.

Plain English
This study looked at the immune response in 9 patients suffering from IgG4-related disease, a condition where the immune system attacks the body, and compared their immune cells to those from 7 healthy people. Researchers found that the patients had a higher number of certain immune cells, like plasmablasts and T cells, which indicates that their immune systems were working harder and were more activated, especially in relation to how many organs were affected by the disease. Understanding these immune patterns is crucial because it may identify new treatment targets to help patients with this autoimmune disease. Who this helps: This research benefits patients with IgG4-related disease by potentially leading to better treatment options.

Plain English
Researchers studied a new treatment for T cell lymphomas, a serious type of blood cancer. They found that a targeted drug called CD6-ADC effectively killed cancer cells and shrank existing tumors in laboratory and mouse tests. This is crucial because it presents a new potential therapy for patients with T cell lymphoma, which currently has limited treatment options. Who this helps: This benefits patients with T cell lymphoma.

Plain English
Researchers studied how inflammation affects gene expression in the skin of people with psoriasis, a persistent skin condition. They analyzed skin samples from 375 patients and identified 953 genetic regions that change with local inflammation. Notably, 116 of these regions showed significant changes linked to inflammation, with the strongest impact observed in a gene related to psoriasis risk found in the outer skin layer. This research helps improve our understanding of psoriasis and may lead to better-targeted treatments. Who this helps: Patients with psoriasis.

Plain English
This study looked at how effective a type of cancer treatment, called PD-1 therapy, is for patients with a specific kind of colon cancer known as dMMR colorectal cancer. They analyzed 38 patients who received the treatment and found that 45% had no signs of cancer when checked with an endoscopy, while 23% showed no signs on imaging tests. The findings highlight a gap between imaging results and actual cancer response, with many patients showing issues despite improvements in some areas, pointing to a need for better ways to measure treatment success. Who this helps: This helps patients with dMMR colorectal cancer and their doctors.

Plain English
This study looked at a specific way to boost the immune system's ability to fight cancer by focusing on a molecule called CD6. Researchers found that using an antibody (UMCD6) to block the interaction between CD6 and a protein found on many cancer cells (CD318) led to better survival rates in mice with breast and prostate cancer. In these mice, more immune cells that attack tumors, like NK and CD8+ T cells, were present and more active compared to those that didn’t receive the treatment. Who this helps: This benefits cancer patients by potentially improving treatment outcomes.

Plain English
Researchers developed a new drug called CD6-ADC, designed to target and kill harmful T cells involved in autoimmune diseases and transplant rejection. In tests, CD6-ADC effectively destroyed activated T cells without harming normal T cells and showed success in treating two models of autoimmune eye disease and one model of graft versus host disease. This is important because it offers a new way to specifically target and manage conditions caused by overactive T cells. Who this helps: Patients with autoimmune diseases and those undergoing organ transplants.

Plain English
This study looked at how a herbal compound called cepharanthine (CEP) affects rheumatoid arthritis (RA) by targeting certain immune cells known as macrophages. The researchers found that CEP significantly reduced joint inflammation and damage in a mouse model of RA, lowering harmful substances like TNF-α and decreasing the number of M1 macrophages, which are linked to inflammation. This is important because it shows that CEP may offer a new way to treat RA, potentially helping patients manage their symptoms better. Who this helps: Patients with rheumatoid arthritis.

Plain English
This study looked at a type of tiny genetic material called microRNAs (miRNAs) that influence various immune system processes in diseases like rheumatoid arthritis and lupus. The researchers analyzed a large number of existing studies to identify which miRNAs were most commonly associated with these diseases, focusing on the top three: miR-146, miR-155, and miR-21. They found that these miRNAs play important roles in several conditions, helping to highlight where more research is needed, and guiding scientists toward potential new treatments. Who this helps: Patients with rheumatic diseases and researchers developing new therapies.

Plain English
This study looked at early changes in metabolism and cell function in the retinas of newborn mice that model a common genetic eye disease. Researchers found that before any visible damage occurred, there were significant drops in energy-related genes and problems with cell signaling, particularly involving calcium, which led to early stress in cellular structures called mitochondria. These findings are important because they highlight potential early markers for retinal degeneration, which could help in developing treatments to protect vision. Who this helps: This helps patients with genetic retinal diseases and their doctors seeking early intervention strategies.

Plain English
This study looked at how blocking certain proteins called bromodomain extraterminal (BET) proteins can help reduce skin thickening in a condition known as scleroderma. The researchers found that using a drug called JQ1 to inhibit these proteins led to a significant reduction in fibrosis in lab animals and skin cells from scleroderma patients. Specifically, they observed changes in gene activity that affect cell growth and calcium levels, which are important for managing tissue fibrosis. Who this helps: This benefits patients with scleroderma by offering potential new treatment options.

Plain English
This study looked at how to accurately estimate the number of breeding Atlantic sturgeon in the Delaware River using genetic data from their juvenile offspring, rather than needing to sample adults directly. The researchers found that if enough genetic information is available, their estimates can be very accurate, but even with limited data, understanding potential errors in the data helps make better estimates. They discovered that the current breeding population of Atlantic sturgeon is likely to be much smaller—about 1,000 times—than what was historically recorded, which is important for guiding conservation efforts. Who this helps: This benefits conservationists and environmental agencies working to protect endangered species.

Plain English
Scientists studied the health and nutrition of 153 wild Sand Tiger sharks in Delaware Bay by examining their blood samples. They found that juvenile sharks had higher levels of certain blood components like glucose and white blood cells compared to adults, and they identified important reproductive hormones that could help improve breeding in captivity. Overall, this research provides key health guidelines for caring for Sand Tigers in aquariums and aids efforts to manage their populations sustainably. Who this helps: This helps aquarium staff and conservationists working with shark populations.

Plain English
This study looked at the effects of a drug called tofacitinib on patients with systemic sclerosis, an autoimmune disease that causes thickening of the skin and can affect other organs. In a trial with 15 participants, the drug was found to be safe, with no serious side effects reported. Tofacitinib also showed promising results in reducing certain gene expressions related to the disease in skin cells, suggesting that the drug may help improve skin and organ health in these patients. Who this helps: This research helps patients with systemic sclerosis.

Plain English
This study looked at how a protein called CDCP1 affects the health of cells in the eye that are important for vision. Researchers found that mice lacking CDCP1 showed less eye inflammation when induced with autoimmune uveitis; specifically, these mice had more stable cell connections in the eye compared to regular mice. This is important because it suggests that targeting CDCP1 could help prevent or reduce eye inflammation in similar conditions. Who this helps: This helps patients with autoimmune eye diseases.

Plain English
This study looked at how some immune system weaknesses, known as immunodeficiencies, can actually lead to autoimmune problems, where the body attacks its own cells. Researchers focused on a specific condition called purine nucleoside phosphorylase (PNP) deficiency, finding that in this case, a part of the immune system was overactive, which contributed to the autoimmune issues. Understanding this relationship helps explain why people with weak immune systems can also face autoimmune diseases, highlighting the complexity of our immune responses. Who this helps: This benefits patients with autoimmune diseases related to immune deficiencies.

Plain English
This study examined a protein called extracellular sulfatase-2 (Sulf-2) in patients with rheumatoid arthritis (RA). Researchers found that Sulf-2 levels were significantly higher in the blood and joint tissues of RA patients compared to healthy individuals. Specifically, knocking down Sulf-2 reduced the expression of about 2,500 genes and lowered signs of inflammation in joint cells, suggesting that targeting Sulf-2 could be a new approach for treating RA. Who this helps: This research benefits patients with rheumatoid arthritis by potentially leading to new treatments.

Plain English
This study examined a 14-year-old girl who had brain lesions that looked like multiple sclerosis but were actually caused by IgG4-related disease (IgG4-RD). The girl experienced symptoms like double vision and weakness, and tests showed high levels of certain antibodies associated with IgG4-RD. She treated successfully with medications, including glucocorticoids. Understanding this condition is important because it helps doctors differentiate between IgG4-RD and multiple sclerosis, which can lead to more accurate diagnoses and better treatment for patients. Who this helps: Patients with similar symptoms, healthcare providers, and researchers studying autoimmune diseases.

Plain English
This study looks at how CD6, a molecule in the immune system, plays a role in both cancer and autoimmune diseases. Researchers found that CD6 can be a potential target for treatments since it affects how the immune system reacts to both cancer cells and self-antigens, the body's own proteins that can trigger autoimmune responses. This is important because finding ways to effectively manage cancer treatment while minimizing autoimmune issues could greatly improve patient outcomes. Who this helps: This helps patients with cancer and autoimmune diseases, as well as their doctors.

Plain English
Researchers studied the effects of a medication called abatacept in 84 patients with early diffuse systemic sclerosis (dcSSc), focusing on those with high inflammation levels. After a year, patients receiving abatacept showed significant skin improvement, with a better reduction in skin scores than those taking a placebo—specifically, those with high inflammation levels had a notable shift in their gene expression towards a healthier state. This research highlights how tailored treatments can lead to better outcomes for specific patient groups. Who this helps: This helps patients with early systemic sclerosis who have high inflammation levels.

Plain English
Researchers discovered that a protein called CD13, which leaks into the bloodstream, causes inflammatory arthritis by activating a receptor called B1R found on joint cells. They confirmed this by showing that blocking B1R with drugs stopped the inflammation in multiple types of arthritis in mice and in human joint tissue samples. This matters because B1R could be a new drug target to treat rheumatoid arthritis and other inflammatory diseases by preventing CD13 from triggering joint inflammation.

Plain English
This study developed a mobile warning system using satellite data to help protect the endangered Atlantic sturgeon in the Delaware Bay. The system accurately predicted where these fish would be about 90% of the time over a three-day period. This matters because it allows fishermen and state managers to avoid areas where sturgeons are present, helping to conserve the species while still managing fishing activities effectively. Who this helps: This helps fishermen and conservation managers.

Plain English
This study looked at how well COVID-19 mRNA vaccines work in people with multiple sclerosis (MS) and neuromyelitis optica (NMO) who are on specific treatments that deplete B-cells. Among 53 participants, only 36.4% of those on B-cell depleting therapies produced a positive antibody response to the vaccine, compared to 100% of healthy individuals and those not on these therapies. This matters because it shows that patients on B-cell depleting treatments may not get adequate protection from COVID-19 vaccines, highlighting a need for tailored vaccination strategies for these groups. Who this helps: Patients with multiple sclerosis and neuromyelitis optica on B-cell depleting therapies.

Plain English
This study looked at how doctors from different specialties—internal medicine, pediatrics, and surgery—perceive and use narrative medicine, which involves listening to patients' stories to improve care. Interviews with 15 senior physicians showed that while primary care doctors view narrative medicine as crucial for their practice, surgeons also find it helpful but face different challenges, like dealing with logistics and patient data. Understanding these differences can help tailor narrative medicine training to better fit each specialty's needs and improve patient care overall. Who this helps: This helps doctors improve patient interactions and care strategies tailored to their specialties.

Plain English
This study examined the medication abatacept in patients with early diffuse cutaneous systemic sclerosis, a serious autoimmune disease, over a total of 18 months. The results showed that those treated with abatacept had an average skin score improvement of 9.8 points by month 18, while those initially receiving a placebo improved by 6.3 points, indicating that the treatment appears effective in reducing skin symptoms. Importantly, no new safety concerns emerged during the study, suggesting that abatacept is safe for patients with this condition. Who this helps: This helps patients with diffuse cutaneous systemic sclerosis and their doctors in managing the disease.